Immune Reset Protocol

Overview

The immune system operates as a finely tuned network of checks and balances between pro-inflammatory and anti-inflammatory pathways. When this balance is disrupted — by chronic infection, environmental triggers, or autoimmune processes — the result can be a dysfunctional immune state characterized by either excessive activation (autoimmunity, chronic inflammation) or inadequate response (recurrent infections, slow recovery).

An "immune reset" protocol aims to rebalance rather than simply stimulate or suppress the immune system. The two primary peptides in this framework — thymosin alpha-1 (Ta1) and LL-37 — work through immunomodulatory rather than purely immunostimulatory mechanisms, making them distinct from compounds that simply "boost" immune activity.

This protocol is relevant for individuals dealing with chronic or recurrent infections, post-infectious immune dysregulation (including long COVID-type presentations), and Th1/Th2 imbalance patterns. For acute immune support needs, see the Immune Support Protocol.

Compounds Involved

Compound	Class	Primary Effects	Route	Typical Dose
Thymosin alpha-1	Thymic peptide	T-cell maturation, Th1/Th2 balance, NK cell activation	SubQ	1.6 mg 2–3x/week
LL-37	Cathelicidin (antimicrobial peptide)	Direct antimicrobial, immune modulation, biofilm disruption	SubQ	50–100 mcg/day
Vitamin D3	Secosteroid hormone	Immune regulation, cathelicidin expression	Oral	5,000–10,000 IU/day
Zinc	Essential mineral	Thymic function, T-cell development	Oral	30–50 mg/day

Thymosin Alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue. It is the only peptide immunomodulator approved as a pharmaceutical drug in multiple countries (marketed as Zadaxin) for hepatitis B and C treatment and as an adjuvant to cancer immunotherapy.

Ta1 works primarily through maturation and differentiation of T lymphocytes, enhancement of natural killer (NK) cell cytotoxicity, promotion of dendritic cell maturation, and modulation of the Th1/Th2 balance. Its immunomodulatory (rather than purely stimulatory) profile means it can help both underactive and overactive immune states — upregulating response when needed and promoting tolerance when the immune system is overreactive.

LL-37

LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans. It is produced by neutrophils, macrophages, and epithelial cells as a first-line defense against pathogens. Synthetic LL-37 has been studied for direct antimicrobial activity against bacteria, viruses, and fungi, disruption of bacterial biofilms (structured communities resistant to antibiotics), modulation of inflammatory cytokine profiles, and promotion of wound healing and angiogenesis.

LL-37 is particularly relevant for chronic infections where biofilm formation impedes conventional antibiotic treatment.

Protocol Structure

Phase 1: Foundation and Assessment (Weeks 1–2)

Establish baseline immune status and begin nutritional support.

Blood work: Request comprehensive immune panels before starting:

• Complete blood count with differential (lymphocyte subsets)
• Immunoglobulin levels (IgG, IgA, IgM, IgE)
• Vitamin D (25-OH) — target 50–70 ng/mL
• Zinc (serum or RBC) — target upper-normal range
• CRP and ESR (inflammatory markers)
• Th1/Th2 cytokine panel if available (TNF-alpha, IL-6, IL-10, IFN-gamma)

See Blood Work Monitoring for comprehensive guidance.

Nutritional foundation:

Supplement	Dose	Timing
Vitamin D3	5,000–10,000 IU	Morning with fat-containing meal
Zinc (picolinate or bisglycinate)	30–50 mg	With food (avoid taking with iron)
Vitamin C	1,000–2,000 mg	Divided doses throughout the day
Selenium	200 mcg	With food

Phase 2: Thymosin Alpha-1 Introduction (Weeks 3–10)

Begin Ta1 while continuing the nutritional foundation.

Peptide protocol:

Compound	Dose	Frequency	Route
Thymosin alpha-1	1.6 mg	2x per week (e.g., Monday/Thursday)	SubQ

• Inject subcutaneously in the abdominal area, rotating sites
• Administer in the morning for alignment with natural immune circadian rhythms
• Some protocols increase to 3x per week for the first 2–4 weeks as a loading phase

Monitoring: Track energy levels, frequency of infections or illness, and any symptom changes. Repeat CRP and immune markers at week 6 if initial values were abnormal.

Phase 3: LL-37 Addition (Weeks 6–14)

For individuals with chronic infections, biofilm-associated conditions, or persistent respiratory issues, add LL-37 to the Ta1 base.

Combined protocol:

Compound	Dose	Frequency	Route
Thymosin alpha-1	1.6 mg	2–3x per week	SubQ
LL-37	50–100 mcg	Daily for 4–6 weeks	SubQ

• LL-37 courses are typically shorter (4–6 weeks) due to limited long-term safety data
• For respiratory-focused applications, see the Respiratory Protocol
• LL-37 can cause injection site reactions (redness, warmth) — this is related to its immune-activating properties and typically resolves within hours

Phase 4: Maintenance (Ongoing)

After the initial treatment course, transition to a maintenance approach.

Maintenance protocol:

Compound	Dose	Frequency	Duration
Thymosin alpha-1	1.6 mg	1–2x per week	Ongoing or seasonal
Vitamin D3	5,000 IU	Daily	Ongoing (dose-adjusted to blood levels)
Zinc	15–30 mg	Daily	Ongoing

Ta1 maintenance can be continuous at the lower frequency or used seasonally (e.g., fall/winter months when infection risk increases). Some protocols employ a cyclical approach: 8 weeks on, 4 weeks off, repeating as needed. See Peptide Cycling.

Specific Applications

Post-Infectious Immune Dysregulation

Post-COVID and other post-viral syndromes often involve persistent immune activation, T-cell exhaustion, and Th1/Th2 imbalance. Ta1's ability to promote T-cell maturation and rebalance immune subsets makes it particularly relevant. Combined with the Brain Fog Protocol when cognitive symptoms are present.

Recurrent Infections

Individuals with frequent upper respiratory infections, UTIs, or other recurrent infections may benefit from the immune priming effects of Ta1 combined with LL-37's direct antimicrobial properties. Ensure underlying immunodeficiency has been ruled out with appropriate testing.

Autoimmune Considerations

Ta1's immunomodulatory (not purely immunostimulatory) profile means it has been studied in some autoimmune contexts. However, use in autoimmune conditions should be approached with caution and under medical supervision, as immune modulation in the wrong direction could theoretically worsen certain autoimmune presentations.

Lifestyle Integration

• Sleep: Immune function is profoundly affected by sleep quality. Growth hormone and immune cytokines are released during deep sleep. See Sleep Optimization Protocol.
• Stress management: Chronic psychological stress suppresses immune function through cortisol-mediated pathways. Incorporate stress reduction practices.
• Exercise: Moderate exercise enhances immune surveillance. Avoid overtraining, which can be immunosuppressive. See Peptides and Lifestyle.
• Gut health: Approximately 70% of immune tissue resides in the gut-associated lymphoid tissue (GALT). Gut health directly impacts immune function. See Gut Healing Protocol.

Important Considerations

• Medical supervision recommended: Immune modulation should ideally be guided by a healthcare provider familiar with immunology, particularly for individuals with autoimmune conditions.
• Herxheimer-like reactions: Some individuals experience a temporary worsening of symptoms (fatigue, malaise, mild fever) when beginning immune-modulating peptides. This is thought to represent increased immune activity against existing pathogens and typically resolves within days.
• Not for acute illness: This protocol is for chronic immune rebalancing, not acute infection treatment. During active illness, standard medical care takes priority.
• Quality critical: Immune-modulating peptides must be high-purity. Contaminants in poorly manufactured peptides could trigger unpredictable immune responses. See Purity and Testing.
• Storage: Ta1 and LL-37 require proper reconstitution and refrigerated storage. See Reconstitution and Storage.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.